To determine whether the induction of Notch3 and β-catenin signaling is observed in human EGFR mutant NSCLC, we evaluated Notch3 and β-catenin levels in human lung cancer biopsies before and after erlotinib therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.